RenovoRx, Inc. Overview
Pro stress-test →RenovoRx, Inc. is a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, U.S. Food and Drug Administration (FDA)-cleared local drug-delivery device, targeting high unmet medical needs. RenovoRx's patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
Strategic Profile
Pro stress-test →RenovoRx achieved key milestones in the commercial launch of RenovoCath in 2025, its first full year of generating revenue with a growing adoption of TAMP enabled by RenovoCath in cancer centers throughout the United States, with early commercial traction reflecting increasing physician interest in targeted intra-arterial drug-delivery. RenovoRx estimates that the initial total addressable market (TAM) for RenovoCath as a stand-alone device represents an approximately $400 million peak annual U.S. sales opportunity, and ultimately a multi-billion-dollar potential as the platform expands into additional solid tumor indications.
Competitive Landscape
Pro stress-test →RenovoRx competes in the targeted combination therapies and drug delivery device space, with its lead product RenovoCath providing chemotherapy gemcitabine through targeted intra-arterial delivery in Phase III clinical trials for locally advanced pancreatic cancer. Direct competitors in localized oncology drug delivery and pancreatic cancer treatment include established players like Varian (radiotherapy), Ono Pharmaceutical, and various systemic chemotherapy providers.
Industry Context
RenovoRx, Inc. operates in Biotechnology/Medical Devices - Oncology.
Key facts
Founded: 2009 · Headquarters: Mountain View, US · Revenue: $1.1M · Market cap: $41.4M